Oregon State Archives

Oregon Bulletin

July 1, 2011

Oregon Board of Naturopathic Medicine
Chapter 850

Rule Caption: Clarify the certification process for Natural Childbirth.

Adm. Order No.: OBNM 3-2011

Filed with Sec. of State: 6-15-2011

Certified to be Effective: 6-15-11

Notice Publication Date: 5-1-2011

Rules Amended: 850-035-0230

Subject: Clarify the certification process for Natural Childbirth.

Rules Coordinator: Anne Walsh—(971) 673-0193

850-035-0230

Requirements for Certification to Practice Natural Childbirth

A naturopathic physician maintaining an active license in Oregon, who wishes to practice natural childbirth must apply to and receive from the board a certificate of special competency in natural childbirth. To receive and maintain a certificate, the licensee must fulfill the following requirements:

(1) Complete at least 200 hours of course work at an approved naturopathic college or hospital in obstetrics and furnish a signed log showing evidence that (a) and (b) and (c) of this subsection have been completed under the direct supervision of a licensed practitioner with specialty training in obstetrics and/or natural childbirth:

(a) Licensee must have taken part in the care of 50 cases each in prenatal and postnatal care; one case may qualify for both areas of care; and

(b) Licensee must have observed and assisted in the intrapartum care and delivery of 50 natural childbirths in a hospital or alternative birth setting. A minimum of 26 of these births must be under the supervision of a naturopathic doctor. No more than 10 of the 50 births may be under the supervision of a medical doctor. No more than 10 of the births may be observation only. A labor and delivery that starts under the care of a naturopathic doctor and includes hospitalization shall count as a birth; and

(c) Licensee must hold a current neonatal resuscitation certificate.

(2) Licensee must pass a specialty exam in obstetrics given by or approved by the Board, after first completing the 200 hours of coursework as required above, and participating in the care of at least 15 cases each in prenatal, intrapartum, and postnatal care; one case may qualify for all these areas of care.

(3) Review of birth records as required by (1)(b) must be completed and approved by a Board appointed licensee of this Board holding a certificate of special competency in natural childbirth for at least five years.

(4) A complete application for a certificate of special competency in natural childbirth must be submitted within three years of passing the specialty examination and must include:

(a) A completed application form furnished by the Board;

(b) A reviewed and approved birth log, meeting all the requirements of this rule:

(c) Verification of passage of an approved specialty examination per subsection (2) of this rule;

(d) Current neonatal resuscitation certification; and

(e) Appropriate fee(s) per OAR 850-0035.

(5) Licensee holding a natural childbirth certification must annually, including initial year of certification, submit 15 hours of Board approved continuing education in obstetrics, which may be used to satisfy ORS 685.102. Licensee must submit proof of current certification in neonatal resuscitation annually.

(6) Licensing action by the Board under ORS 685.100 shall be deemed to have an equal effect upon a certificate of special competency issued the practitioner, unless specifically provided otherwise in the Board action. When the subject of a disciplinary proceeding under 685.100 relates specifically to the practice of natural childbirth by a licensee who possesses a certificate of special competency, the license action may in lieu of effecting the entire scope of the licensee’s practice, suspend, revoke, or curtail only the practitioner’s authority under a certificate of special competency.

Stat. Auth.: ORS 183 & 685

Stats. Implemented: ORS 685.100, 685.102, 685.135 & 685.160

Hist.: NE 3-1985(Temp), f. & ef. 9-23-85; NE 1-1986, f. & ef. 4-10-86; NE 1-1996, f. & cert. ef. 10-18-96; NE 2-1997(Temp), f. 12-1-97, cert. ef. 12-2-97 thru 5-31-98; administrative correction 8-9-99; BNE 1-2001, f. & cert. ef. 2-7-0; Renumbered from 850-010-0230, BNE 8-2005, f. & cert. ef. 10-27-05; BNE 1-2009, f. & cert. ef. 4-30-09; BNE 4-2009, f. & cert. ef. 10-6-09; BNE 5-2009(Temp), f. & cert. ef. 10-13-09 thru 12-31-09; BNE 6-2009, f. 11-2-09, cert. ef. 1-1-10; OBNM 3-2011, f. & cert. ef. 6-15-11

Rule Caption: Rule removes the Mifepristone from Formulary Compendium.

Adm. Order No.: OBNM 4-2011

Filed with Sec. of State: 6-15-2011

Certified to be Effective: 6-15-11

Notice Publication Date: 5-1-2011

Rules Amended: 850-060-0226

Subject: Rules removes Mifepristone from classification (21)
Oxytocics.

Rules Coordinator: Anne Walsh—(971) 673-0193

850-060-0226

Formulary Compendium Classifications

The Formulary Council has approved the following pharmacologic-therapeutic classifications in addition to drugs previously approved by the Formulary Council and listed in 850-060-0225. This listing does not supersede the education and training requirement established in 850-060-0212 for administration of IV agents. The Formulary Council may consider new agents, substances and pharmacologic-therapeutic classifications for addition to this list.

(1) Antihistamine Drugs;

(a) First Generation Antihistamine Drugs;

(A)Ethanolamine Derivatives;

(B) Ethylenediamine Derivatives;

(C) Phenothiazine Derivatives;

(D) Piperazine Derivatives;

(E) Propylamine Derivatives;

(F) Miscellaneous Derivatives;

(b) Second Generation Antihistamines.

(2) Anti-Infective Agents;

(a) Antihelmintics;

(b) Antibacterials;

(A) Aminoglycosides;

(B) Cephalosporins;

(i) First Generation Cephalosporins;

(ii) Second Generation Cephalosporins;

(iii) Third Generation Cephalosporins;

(iv) Fourth Generation Cephalosporins.

(C) Miscellaneous β-Lactams;

(i) Carbacephems;

(ii) Carbapenems;

(iii) Cephamycins;

(iv) Monobactams.

(D) Chloramphenicol;

(E) Macrolides.

(i) Erythromycins;

(ii) Ketolides;

(iii) Other Macrolides.

(F) Penicillins;

(i) Natural Penicillins;

(ii) Aminopenicillins;

(iii) Penicillinase-resistant Penicillins;

(iv) Extended-spectrum Penicillins.

(G) Quinolones;

(H) Sulfonamides;

(I) Tetracyclines: Glycylcyclines;

(J) Antibacterials, Miscellaneous.

(i) Aminocyclitols;

(ii) Bacitracins;

(iii) Cyclic Lipopeptides;

(iv) Glycopeptides;

(v) Lincomycins;

(vi) Oxazolidinones;

(vii) Polymyxins;

(viii) Rifamycins;

(ix) Streptogramins;

(c) Antifungals;

(A) Allylamines;

(B) Azoles;

(C) Echinocandins;

(D) Polyenes;

(E) Pyrimidines;

(F) Antifungals, Miscellaneous.

(d) Antimycobacterials;

(A) Antituberculosis Agents;

(B) Antimycobacterials, Miscellaneous.

(e) Antivirals;

(A) Adamantanes;

(B) Antiretrovirals;

(i) HIV Fusion Inhibitors;

(ii) HIV Protease Inhibitors;

(iii) Integrase Inhibitors;

(iv) Nonnucleoside Reverse Transcriptase Inhibitors;

(v) Nucleoside and Nucleotide Reverse Transcriptase Inhibitors

(C) Interferons;

(D) Monoclonal Antibodies;

(E) Neuraminidase Inhibitors;

(F) Nucleosides and Nucleotides;

(G) Antivirals, Miscellaneous;

(f) Antiprotozoals;

(A) Amebicides;

(B) Antimalarials;

(C) Antiprotozoals, Miscellaneous.

(3) Antineoplastic Agents (oral and topical only) limited to the following:

(a) 5FU;

(b) Anastrozole;

(c) Letrozole;

(d) Megestrol;

(e) Mercaptopunne;

(f) Methotrexate;

(g) Tamoxifen;

(h) Tretinoin.

(4) Autonomic Drugs;

(a) Parasympathomimetic (Cholinergic) Agents;

(b) Anticholinergic Agents: Antimuscarinics/ Antispasmodics;

(c) Sympathomimetic (Adrenergic) Agents;

(A) α-Adrenergic Agonists;

(B) β- Adrenergic Agonists;

(i) Non-selective β- Adrenergic Agonists;

(ii) Selective β1- Adrenergic Agonists;

(iii) Selective β2- Adrenergic Agonists;

(C) α-And β-Adrenergic Agonists;

(d) Sympatholytic (Adrenergic Blocking) Agents;

(e) Skeletal Muscle Relaxants;

(A) Centrally Acting Skeletal Muscle Relaxants;

(B) Direct-acting Skeletal Muscle Relaxants;

(C) GABA-derivative Skeletal Muscle Relaxants;

(D) Neuromuscular Blocking Agents;

(E) Skeletal Muscle Relaxants, Miscellaneous.

(f) Autonomic Drugs, Miscellaneous.

(5) Blood Derivatives.

(6) Blood Formation, Coagulation, and Thrombosis;

(a) Antianemia Drugs: Iron Preparations;

(b)(A) Antithrombotic Agents;

(B) Anticoagulants;

(i) Coumarin Derivatives;

(ii) Direct Thrombin Inhibitors;

(iii) Heparins;

(iv) Anticoagulants, Miscellaneous.

(c) Platelet-reducing Agents;

(d) Platelet-aggregation Inhibitors;

(e) Thrombolytic Agents;

(f) Hematopoietic Agents;

(g) Hemorrheologic Agents;

(h) Antihemorrhagic Agents;

(A) Antiheparin Agents;

(B) Hemostatics.

(7) Cardiovascular Drugs;

(a) Cardiac Drugs;

(A) Antiarrhythmic Agents;

(i) Class Ia Antiarrhythmics;

(ii) Class Ib Antiarrhythmics;

(iii) Class Ic Antiarrhythmics;

(iv) Class III Antiarrhythmics;

(v) Class IV Antiarrhythmics.

(B) Cardiotonic Agents;

(C) Cardiac Drugs, Miscellaneous.

(b) Antilipemic Agents;

(A) Bile Acid Sequestrants;

(B) Cholesterol Absorption Inhibitors;

(C) Fibric Acid Derivatives;

(D) HMG-CoA Reductase Inhibitors;

(E) Antilipemic Agents, Miscellaneous.

(c) Hypotensive Agents;

(A) Calcium-Channel Blocking Agents;

(B) Central a-Agonists;

(C) Direct Vasodilators;

(D) Peripheral Adrenergic Inhibitors.

(d) Vasodilating Agents;

(A) Nitrates and Nitrites;

(B) Phosphodiesterase Inhibitors;

(C) Vasodilating Agents, Miscellaneous.

(e) Sclerosing Agents;

(f) α-Adrenergic Blocking Agents;

(g) β-Adrenergic Blocking Agents;

(h) Calcium-Channel Blocking Agents;

(A) Dihydropyridines;

(B) Calcium-Channel Blocking Agents, Miscellaneous;

(i) Renin-Angiotensin-Aldosterone System Inhibitors;

(A) Angiotensin-Converting Enzyme Inhibitors;

(B) Angiotensin II Receptor Antagonists;

(C) Mineralocorticoid (Aldosterone) Receptor Antagonists;

(D) Renin Inhibitors.

(8) Central Nervous System Agents;

(a) Analgesics and Antipyretics;

(A) Nonsteroidal Anti-inflammatory Agents;

(i) Cyclooxygenase-2 (COX-2) Inhibitors;

(ii) Salicylates;

(iii) Other Nonsteroidal Anti-inflammatory Agents;

(B) Opiate Agonists;

(C) Opiate Partial Agonists;

(D) Analgesics and Antipyretics, Miscellaneous.

(b) Opiate Antagonists;

(c) Anticonvulsants, does not include Barbiturates;

(A) Benzodiazepines;

(B) Hydantoins;

(C) Succinimides;

(D) Anticonvulsants, Miscellaneous.

(d) Psychotherapeutic Agents;

(A) Antidepressants;

(i) Monoamine Oxidase Inhibitors;

(ii) Selective Serotonin- and Norepinephrine-reuptake Inhibitors;

(iii) Selective Serotonin- Reuptake Inhibitors;

(iv) Serotonin Modulators;

(v) Tricyclics and Other Norepinephrine-reuptake Inhibitors.

(vi) Antidepressants, Miscellaneous.

(B) Antipsychotics, to include only the following: Atypical antipsychotics.

(e) Anorexigenic Agents and Respiratory and Cerebral Stimulants.

(A)Amphetamines.

(B) Anorexigenic Agents and Respiratory and Cerebral Stimulants, Miscellaneous.

(f) Anxiolytics, Sedatives, and Hypnotics, does not include Barbiturates;

(A) Benzodiazepines;

(B) Anxiolytics, Seditives, and Hypnotics; Miscellaneous;

(g) Antimanic Agents;

(h) Antimigraine Agents: Selective Serotonin Agonists;

(i) Antiparkinsonian Agents;

(A) Adamantanes;

(B) Anticholinergic Agents;

(C) Catechol-O-Methyltransferase (COMT) Inhibitors;

(D) Dopamine Precursors;

(E) Dopamine Receptor Agonists;

(i) Ergot-derivative Dopamine Receptor Agonists;

(ii) Non-ergot-derivative Dopamine Receptor Agonists;

(F) Monoamine Oxidase B Inhibitors;

(j) Central Nervous System Agents, Miscellaneous.

(9) Contraceptives (foams, devices).

(10) Diagnostic Agents.

(11) Disinfectants (for Agents used on objects other than skin).

(12) Electrolytic, Caloric, and Water Balance;

(a) Acidifying Agents;

(b) Alkalinizing Agents;

(c) Ammonia Detoxicants;

(d) Replacements Preparations;

(e) Ion-Removing Agents;

(A) Calcium-removing Agents;

(B) Potassium-removing Agents;

(C) Phosphate-removing Agents;

(D) Other Ion-removing Agents;

(f) Caloric Agents;

(g) Diuretics;

(A) Loop Diuretics;

(B) Osmotic Diuretics;

(C) Potassium-sparing Diuretics;

(D) Thiazide Diuretics;

(E) Thiazide-like Diuretics;

(F) Diuretics, Miscellaneous;

(h) Irrigation Solutions;

(i) Uricosuric Agents.

(13) Enzymes.

(14) Respiratory Tract Agents;

(a) Antihistamines;

(b) Antitussives;

(c) Anti-inflammatory Agents;

(A) Leukotriene Modifiers;

(B) Mast-cell Stabilizers;

(d) Expectorants;

(e) Pulmonary Surfactants;

(f) Respiratory Agents, Miscellaneous.

(15) Eye, Ear, Nose, and Throat (EENT) Preparations;

(a) Antiallergic Agents;

(b) Anti-infectives;

(A) Antibacterials;

(B) Antifungals;

(C) Antivirals;

(D) Anti-infectives, Miscellaneous.

(c) Anti-inflammatory Agents;

(A) Corticosteroids;

(B) Nonsteroidal Anti-inflammatory Agents;

(C) Anti-inflammatory Agents, Miscellaneous.

(d) Local Anesthetics;

(e) Mydriatics;

(f) Mouthwashes and Gargles;

(g) Vasoconstrictors;

(h) Antiglaucoma Agents;

(A) α-Adrenergic Agonists;

(B) β-Adrenergic Agents;

(C) Carbonic Anhydrase Inhibitors;

(D) Miotics;

(E) Prostaglandin Analogs;

(i) EENT Drugs, Miscellaneous.

(16) Gastrointestinal Drugs;

(a) Antacids and Adsorbents;

(b) Antidiarrhea Agents;

(c) Antiflatulents;

(d) Cathartics and Laxatives;

(e) Cholelitholytic Agents;

(f) Emetics;

(g) Antiemetics;

(A) Antihistamines;

(B) 5-HT3 Receptor Antagonists;

(C) Antiemetics, Miscellaneous.

(h) Antiulcer Agents and Acid Suppressants;

(A) Histamine H2-Antogonists;

(B) Prostaglandins;

(C) Protectants;

(D) Proton-pump Inhibitors;

(i) Prokinetic Agents;

(j) Anti-inflammatory Agents;

(k) GI Drugs, Miscellaneous.

(17) Gold Compounds.

(18) Heavy Metal Antagonists.

NOTE: IVadministration requires education and training compliance with 850-060-0212.

(19) Hormones and Synthetic Substitutes;

(a) Adrenals;

(b) Androgens;

(c) Contraceptives;

(d) Estrogens and Antiestrogens;

(A) Estrogens;

(B) Estrogen Agonists-Antiagonists.

(e) Gonadotropins;

(f) Antidiabetic Agents;

(A) α-Glucosidase Inhibitors;

(B) Amylinomimetics;

(C) Biguanides;

(D) Dipeptidyl Peptidase (DDP-4) Inhibitors;

(E) Incretin Mimetics;

(F) Insulins;

(G) Meglitinides;

(H) Sulfonylureas;

(I) Thiazolidinediones.

(g) Antihypoglycemic Agents: Glycogenolytic Agents;

(h) Parathyroid;

(i) Pituitary;

(j) Somatotropin Agonists and Antagonists;

(A) Somatotropin Agonists;

(B) Somatotropin Antagonists;

(k) Progestins;

(l) Thyroid and Antithyroid Agents;

(A) Thyroid Agents;

(B) Antithyroid Agents.

(20) Local Anesthetics.

(21) Oxytocics, except for Mifepristone.

(22) Serums, Toxoids, and Vaccines;

(a) Serums;

(b) Toxoids;

(c) Vaccines.

(23) Skin and Mucous Membrane Agents;

(a) Anti-infectives;

(A) Antibacterials;

(B) Antivirals;

(C) Antifungals;

(i) Allylamines;

(ii) Azoles;

(iii) Benzylamines;

(iv) Hydroxypyridones;

(v) Polyenes;

(vi) Thiocarbamates;

(vii) Antifungals, Miscellaneous.

(D) Scabicides and Pediculicides;

(E) Local Anti-infectives, Miscellaneous.

(b) Anti-inflammatory Agents;

(c) Antipruritics and Local Anesthetics;

(d) Astringents;

(e) Cell Stimulants and Proliferants;

(f) Detergents;

(g) Emollients, Demulcents, and Protectants;

(h) Keratolytic Agents;

(i) Keratoplastic Agents;

(j) Depigmenting and Pigmenting Agents;

(A) Depigmenting Agents;

(B) Pigmenting Agents;

(k) Sunscreen Agents;

(l) Skin and Mucous Membrane Agents, Miscellaneous.

(24) Smooth Muscle Relaxants;

(a) Gastrointestinal Smooth Muscle Relaxants;

(b) Genitourinary Smooth Muscle Relaxants;

(c) Respiratory Smooth Muscle Relaxants.

(25) Vitamins.

(26) Miscellaneous Therapeutic Agents;

(a) Alcohol Deterrents limited to the following:

(A) Acamprosate;

(B) Disulfiram;

(C) Naltrexone.

(b) 5-α Reductase Inhibitors;

(c) Antidotes;

(d) Antigout Agents;

(e) Biologic Response Modifiers, limited to Interferons;

(f) Bone Resorption Inhibitors;

(g) Cariostatic Agents;

(h) Complement Inhibitors;

(i) Disease-Modifying Antirheumatic Agents;

(j) Gonadotropin-releasing Hormone Antagonists;

(k) Immunosuppressive Agents;

(l) Other Miscellaneous Therapeutic Agents limited to the following:

(A) Alfuzosin Hydrochloride;

(B) Drotrecogin Alfa (Activated);

(C) Lanreoytide Acetate;

(D) Rilonacept;

(E) Sapropterin Dihydrochloride;

(F) Tamsulosin Hydrochloride.

Stat. Auth.: ORS 685.125

Stats. Implemented: ORS 685.145

Hist.: BNE 1-2002, f. & cert. ef. 2-19-02; BNE 4-2002, f. & cert. ef. 8-8-02; BNE 3-2003, f. & cert. ef. 6-9-03; BNE 5-2003, f. & cert. ef. 12-5-03; BNE 5-2004, f. & cert. ef. 6-10-04; Renumbered from 850-010-0226, BNE 8-2005, f. & cert. ef. 10-27-05; BNE 9-2005, f. & cert. ef 12-12-05; BNE 4-2006, f. & cert. ef. 12-11-06; BNE 3-2007, f. & cert. ef. 6-12-07; BNE 1-2008, f. & cert. ef. 2-19-08; BNE 2-2008, f. & cert. ef. 3-21-08; BNE 6-2008, f. & cert. ef. 6-11-08; BNE 7-2008, f. & cert. ef. 12-8-08; BNE 2-2009, f. & cert. ef. 6-17-09; BNE 7-2009, f. 12-14-09, cert. ef. 1-1-10; OBNM 5-2010, f. & cert. ef. 6-30-10; OBNM 7-2010, f. & cert. ef. 12-13-10; OBNM 2-2011, f. & cert. ef. 4-12-11; OBNM 4-2011, f. & cert. ef. 6-15-11

Notes
1.) This online version of the OREGON BULLETIN is provided for convenience of reference and enhanced access. The official, record copy of this publication is contained in the original Administrative Orders and Rulemaking Notices filed with the Secretary of State, Archives Division. Discrepancies, if any, are satisfied in favor of the original versions. Use the OAR Revision Cumulative Index found in the Oregon Bulletin to access a numerical list of rulemaking actions after November 15, 2010.

2.) Copyright 2011 Oregon Secretary of State: Terms and Conditions of Use